Mounjaro vs Zepbound: same drug, different rules in 2026

TLDR. Mounjaro and Zepbound are the same molecule (tirzepatide) made by the same manufacturer (Lilly) in the same factory. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for chronic weight management. Insurance covers them under different rules, often with much wider Mounjaro coverage. Cash-pay prices through LillyDirect differ. Some patients qualify clinically for either label but get approved for only one. Off-label prescribing of Mounjaro for weight loss exists but is increasingly difficult in 2026 as plans tighten utilization management. This walks through why the two labels exist, when to push for which and where the rules actually differ.

Why two labels for the same drug

Lilly developed tirzepatide as a dual GLP-1 and GIP receptor agonist. The initial registration trials were diabetes-focused: SURPASS-1 through SURPASS-5 tested tirzepatide head-to-head against semaglutide, insulin and placebo in type 2 diabetes. SURPASS-2 (published in NEJM in 2021) showed tirzepatide 15 mg reduced HbA1c by 2.46 percent and produced 11.2 kg of weight loss in T2D patients, dramatically more than the semaglutide comparator.

The FDA approved tirzepatide for type 2 diabetes in May 2022 under the brand name Mounjaro. Lilly simultaneously ran SURMOUNT-1 through SURMOUNT-4, the obesity-specific trial program in non-diabetic patients. SURMOUNT-1 (NEJM 2022) showed 22.5 percent mean body weight loss at 72 weeks.

The FDA approved tirzepatide for chronic weight management in November 2023 under the brand name Zepbound. The molecule is unchanged. The label, the indication, the pricing structure and the insurance coverage rules are all different.

Lilly's commercial logic: insurance plans treat diabetes medications and weight-loss medications very differently. Maintaining separate brand names and SKUs lets the company sell to both categories without one cannibalizing the other's pricing or coverage. Novo Nordisk runs the same playbook with Ozempic (diabetes) and Wegovy (obesity), both semaglutide.

Insurance treatment: the practical difference

This is where most patients are surprised.

Mounjaro

• Covered by most commercial insurance plans, most Medicaid plans and Medicare Part D
• Prior authorization typically requires: T2D diagnosis (E11.9 ICD-10), prior failed metformin or other oral antidiabetic, A1c above 6.5
• Step therapy often requires failed metformin, sometimes failed semaglutide
• Approval rates: 70 to 85 percent on initial submission with clean documentation
• Tier 2 or 3 on most formularies; copay typically $25 to $100/month

Zepbound

• Covered by some commercial plans, very few Medicaid plans, NOT covered by Medicare for weight loss
• Prior authorization typically requires: BMI 30+ or BMI 27+ with comorbidity, 6 months documented lifestyle modification, sometimes failed Wegovy or Saxenda
• Step therapy often requires failed semaglutide or phentermine
• Approval rates: 45 to 65 percent on initial submission
• Tier 3 or specialty on most formularies that cover it; copay typically $75 to $250/month

Same drug. Very different insurance reality.

Cash-pay prices through LillyDirect

Lilly's direct-to-consumer pricing on LillyDirect shows the brand split as well:

Lilly does not sell Mounjaro through a direct cash-pay channel at a discounted price. Cash-paying for Mounjaro routes through a retail pharmacy at list price, around $1,069/month. Cash-paying for Zepbound through LillyDirect is $349 to $549/month.

The implication: if you have T2D and insurance coverage, Mounjaro is the cheaper path because the copay is low. If you have T2D and no insurance, Zepbound (off-label for diabetes, but legal and the same molecule) is the cheaper cash-pay path at $549 versus $1,069.

When to push for Mounjaro

Three scenarios:

1. You have type 2 diabetes

Mounjaro is the on-label, insurance-friendly option. Approval rates are higher. The clinical evidence for tirzepatide in diabetes is strong (SURPASS-2 head-to-head against semaglutide showed superiority on both A1c and weight). Most prescribers will write Mounjaro by default for T2D patients.

2. You have insurance that covers Mounjaro but not Zepbound

If your insurance lists Mounjaro on the formulary but excludes Zepbound, and you have a borderline diabetes profile (A1c 5.7 to 6.4, prediabetes or insulin resistance), some clinicians will prescribe Mounjaro off-label for prediabetic patients on the rationale that early intervention can prevent progression. This is increasingly contested by insurers, who are running utilization reviews on Mounjaro prescriptions for non-T2D patients.

3. You have a strong family history of T2D and elevated metabolic markers

Patients with fasting insulin above 15, HOMA-IR above 2.5, ApoB elevated, or a first-degree relative with T2D may be appropriately prescribed Mounjaro under a prediabetes or metabolic-syndrome diagnosis. The threshold here is clinical judgment; some prescribers are comfortable with this, others are not.

When to push for Zepbound

Two scenarios:

1. You have BMI 30-plus and no diabetes

Zepbound is the on-label option. Insurance coverage is harder to get, but possible with PA documentation. Cash-pay through LillyDirect is half the price of Mounjaro cash-pay. This is the patient pathway Lilly built Zepbound for.

2. You have BMI 27 to 29.9 with a qualifying comorbidity

Zepbound is on-label at BMI 27-plus with one obesity-related comorbidity (hypertension, dyslipidemia, sleep apnea, atherosclerotic CVD). For these patients, Zepbound PA is feasible. Mounjaro PA on the prediabetes pathway is also possible but increasingly contested.

What SURPASS-2 actually showed

SURPASS-2 was the head-to-head trial of tirzepatide against semaglutide in 1,879 type 2 diabetes patients over 40 weeks. The results, published in NEJM in 2021:

• HbA1c reduction: tirzepatide 15 mg reduced A1c by 2.46 percent; semaglutide 1.0 mg reduced A1c by 1.86 percent. The 0.6 percent gap was statistically significant and clinically meaningful.
• Weight loss: tirzepatide 15 mg produced 11.2 kg loss; semaglutide 1.0 mg produced 5.7 kg loss. Roughly a 2x difference in weight outcome.
• Glycemic target attainment: 86 percent of tirzepatide 15 mg patients reached A1c below 7.0 versus 79 percent on semaglutide.
• Side effects: nausea rates were similar (17-22 percent across doses), with both classes showing the same titration-dependent pattern.

The SURPASS-2 result is the strongest single dataset supporting tirzepatide's clinical superiority in T2D. It is also why most endocrinologists in 2026 default to Mounjaro over Ozempic for new T2D starts when the patient also has a weight-loss goal.

The off-label gray zone

Off-label prescribing of Mounjaro for weight loss in non-diabetic patients was widespread in 2023-2024 when Zepbound coverage was limited. In 2026, three forces have made this more difficult:

• Insurer audits. CVS Caremark, OptumRx and Express Scripts began retrospective review of Mounjaro prescriptions in 2025. Prescriptions without supporting T2D documentation (A1c above 6.5 within the prior 12 months) are increasingly flagged for clawback against the prescriber.
• Step-therapy expansion. Many plans now require failed Wegovy or Zepbound before approving Mounjaro for non-T2D patients, removing the easier-coverage incentive.
• Prescriber liability. Off-label prescribing is legal, but consistent patterns of off-label prescriptions to non-diabetic patients invite scrutiny from state medical boards and DEA review when the medication is also a controlled or scrutinized class.

The practical effect: telehealth programs and PCPs have largely stopped prescribing Mounjaro to non-T2D patients in 2026. Patients who got Mounjaro off-label in 2024 are now being asked to switch to Zepbound on refill.

How to actually get tirzepatide

Decision tree:

1. Do you have type 2 diabetes (A1c above 6.5 documented in chart)? Get Mounjaro. Insurance is the cheap path; cash-pay is expensive.
2. Do you have BMI 30-plus or BMI 27-plus with comorbidity, no T2D? Get Zepbound. Run PA through commercial insurance if your plan covers it; otherwise LillyDirect cash-pay at $349-$549/month.
3. Are you prediabetic (A1c 5.7-6.4) with metabolic syndrome? Discuss with your prescriber. Some will write Mounjaro on the prediabetes pathway; insurance treatment varies and may require appeals.
4. Are you below BMI 27 and not diabetic? Tirzepatide is not appropriate for you on-label under either brand. Discuss with your prescriber whether obesity management is the right framing.

Programs equipped for tirzepatide

Telehealth programs that handle both labels:

• PlushCare, in-network with most major carriers, runs PA on both
• Form Health, obesity-medicine focus, Zepbound-default
• 9amHealth, comorbidity-focused, comfortable with Mounjaro PA for diabetic and prediabetic patients
• Ro Body, branded-focused, both labels available with insurance navigation

Compounded tirzepatide is harder to source legally in 2026. The FDA removed tirzepatide from the shortage list in late 2024, narrowing the 503A compounding legal basis. Many large compounding pharmacies have exited tirzepatide. See our compounded tirzepatide profile for the current state.

Dose equivalence and practical switching

Mounjaro and Zepbound share dose strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. A patient on Mounjaro 10 mg switches to Zepbound 10 mg at the same dose, no re-titration. The pen format is essentially identical; only the labeling and the included instructions reference different indications.

What changes on the switch:

• Insurance treatment: the new prescription triggers a fresh PA, often under different criteria. A T2D patient switching from Mounjaro to Zepbound is now evaluated under the obesity criteria, which may not apply if their BMI is below 30 without comorbidity.
• Pharmacy stocking: some retail pharmacies stock both, some stock only one. Call ahead.
• Savings card: the Mounjaro Savings Card does not transfer; the patient must enroll in the Zepbound Savings Card separately.

Clinically, the switch is invisible. Same molecule, same dose, same delivery, same side-effect profile. Most prescribers treat the switch as a routine prescription change with the standard 28-day refill cycle.

Future state: orforglipron and the next generation

Lilly's oral GLP-1 (orforglipron) is in Phase 3 trials and may be FDA-approved by late 2026 or 2027. Pfizer and Eli Lilly have several other entrants in late-phase development. The branded-product landscape is going to expand, which will likely shift insurance coverage rules again. The lesson from Mounjaro/Zepbound is that the same molecule can have very different commercial paths. Expect that pattern to continue. See our orforglipron profile.

FAQ

Is the medication in a Mounjaro pen and a Zepbound pen actually identical?

Yes. Same active ingredient (tirzepatide), same concentration per dose, same delivery device, same manufacturing facility. The pen label is different and the included instructions reference different indications, but the medication is chemically identical and pharmacologically interchangeable.

Can my prescriber switch me from Mounjaro to Zepbound at the same dose?

Yes. A patient on Mounjaro 7.5 mg weekly can transition to Zepbound 7.5 mg weekly with no titration. The molecule and dose are the same. Most prescribers will write the switch as a routine prescription change. Insurance will treat the switch as a new prescription with new PA requirements; the Mounjaro PA does not transfer to Zepbound.

If I have T2D AND obesity, which brand should I get?

Either is on-label. Mounjaro is usually preferred because diabetes coverage is wider and the copay is lower. The clinical care is identical. Most endocrinologists default to Mounjaro for T2D-plus-obesity patients.

Will the savings cards stack with insurance?

Lilly's Mounjaro Savings Card and Zepbound Savings Card both stack with commercial insurance to reduce copays. Neither stacks with government insurance (Medicare, Medicaid, Tricare, VA). The Zepbound card brings the first month's cost down to $25 and offers up to $150/month off subsequent fills; the Mounjaro card offers similar copay reduction for diabetes patients on commercial insurance.

Is there a price difference at the pharmacy if I cash-pay both?

Yes. Cash-paying for Mounjaro at retail pharmacy: roughly $1,069/month list price. Cash-paying for Zepbound through LillyDirect: $349 to $549/month. Cash-paying for Zepbound at retail pharmacy without using LillyDirect: roughly $1,059/month. The LillyDirect cash channel only exists for Zepbound, not for Mounjaro.